Cleveland BioLabs and Incuron Announce Poster Presentation at ESMO 15th World Congress on Gastrointestinal Cancer

Cleveland BioLabs and Incuron Announce Poster Presentation at ESMO 15th World
Congress on Gastrointestinal Cancer

BUFFALO, N.Y., June 25, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc.
(Nasdaq:CBLI) and Incuron, LLC, a joint venture between CBLI and Bioprocess
Capital Ventures, today announced a poster presentation at the European
Society for Medical Oncology (ESMO) 15^th World Congress on Gastrointestinal
Cancer, July 3-6, 2013 in Barcelona, Spain.

Catherine Burkhart, Ph.D., Director of Oncology Efficacy Evaluation for
Cleveland BioLabs, will present a poster titled, "Curaxin CBL0137 Demonstrates
Significant Antitumor Activity Against FACT-Positive Patient-Derived
Pancreatic Ductal Adenocarcinoma," on July 5, which describes the results of
treatment with CBL0137 in xenograft models.

CBL0137 is a clinical stage oncology drug targeting Facilitates Chromatin
Transcription (FACT) complex, resulting in simultaneous NF-kB suppression,
Heat Shock Factor 1 suppression and p53 activation. A Phase 1, single agent,
dose escalation study of oral administration of CBL0137 in patients with
advanced solid tumors is ongoing in the Russian Federation. In March 2013, a
Notice of Allowance was received from the U.S. Food and Drug Administration
for an Investigational New Drug application for a multi-center, Phase 1,
single agent, dose escalation trial evaluating intravenous administration of
CBL0137 in patients with advanced solid tumors.

The ESMO 15^th World Congress on Gastrointestinal Cancer is a global event,
encompassing malignancies affecting every component of the gastrointestinal
tract and aspects related to the care of patients with gastrointestinal
cancer, including screening, diagnosis and the latest management options for
common and uncommon tumors. For more information about the ESMO World Congress
on Gastrointestinal Cancer, please refer to:

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging
deep mechanistic understanding of the cell death process, apoptosis, to
develop a robust pipeline of compounds primarily focused on oncology
applications and mitigation of radiation injury. The Company's lead compound
is being developed as both a radiation countermeasure and a cancer treatment.
The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs,
Inc., and strategic relationships with the Cleveland Clinic, Roswell Park
Cancer Institute, the Children's Cancer Institute Australia and the Armed
Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs,
Inc., please visit the Company's website at

About Incuron, LLC

Incuron, LLC is a Russian Federation based joint venture founded in 2010
between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures," and
Cleveland BioLabs. Incuron is developing CBL0102 and CBL0137 for oncology and
orphan indications. To learn more about Incuron, LLC, please visit the
company's website at

This press release contains certain forward-looking information about
Cleveland BioLabs that is intended to be covered by the safe harbor for
"forward-looking statements" provided by the Private Securities Litigation
Reform Act of 1995, as amended. Forward-looking statements are statements that
are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s),"
"will," "may," "anticipate(s)" and similar expressions are intended to
identify forward-looking statements. These statements include, but are not
limited to, statements regarding our ability to successfully obtain regulatory
approval for our therapeutic product candidates; statements regarding our
ability to successfully develop and commercialize our therapeutic products;
our ability to expand our long-term business opportunities; the conduct and
results of our various clinical trials; and future performance. All of such
statements are subject to certain risks and uncertainties, many of which are
difficult to predict and generally beyond the control of the Company, that
could cause actual results to differ materially from those expressed in, or
implied or projected by, the forward-looking information and statements.

These factors include, among others, the Company's inability to obtain
regulatory approval in a timely manner or at all; the Company's failure to
develop new products; the Company's collaborative relationships and the
financial risks related thereto; the risks inherent in the early stages of
drug development and in conducting clinical trials. Some of these factors
could cause future results to materially differ from the recent results or
those projected in forward-looking statements.See also the "Risk Factors" and
"Forward-Looking Statements" described in the Company's periodic filings with
the Securities and Exchange Commission.

Rachel Levine, Vice President, Investor Relations
Cleveland BioLabs, Inc.
T: (646) 284-9439

Cleveland BioLabs, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.